Conduit Pharmaceuticals Inc. Files S-1

TL;DR

Conduit Pharma (fka Murphy Canyon Acquisition) filed S-1. Pharma prep biz in San Diego.

AI Summary

Conduit Pharmaceuticals Inc. filed an S-1 form on September 4, 2024, detailing its business operations. The company, formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021, is based in San Diego, California. Its primary business is in pharmaceutical preparations, and it operates under the IRS number 873272543.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding Conduit Pharmaceuticals' business structure, financial status, and future plans as it navigates the pharmaceutical industry.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, it is likely undergoing a significant transition or seeking public investment, which inherently carries market and operational risks.

Key Numbers

• 20240904 — Filing Date (Date the S-1 form was filed with the SEC.)
• 1231 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

• Conduit Pharmaceuticals Inc. (company) — Filer name
• Murphy Canyon Acquisition Corp. (company) — Former company name
• San Diego, CA (location) — Business address
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
• 873272543 (tax_id) — IRS Number
• 333-281933 (sec_file_number) — SEC File Number

FAQ

Key Financial Figures

• $0.0001 — 5 shares of our common stock, par value $0.0001 per share ("Common Stock"), consisting
• $0.1289 — eported on The Nasdaq Global Market was $0.1289 per share. We are an "emerging growth
• $1.5 m — paid AstraZeneca an up-front payment of $1.5 million, and (iii) is obligated to pay As

Filing Documents

• forms-1.htm (S-1) — 3949KB
• ex5-1.htm (EX-5.1) — 14KB
• ex23-1.htm (EX-23.1) — 5KB
• ex107.htm (EX-FILING FEES) — 43KB
• forms-1_001.jpg (GRAPHIC) — 6KB
• ex5-1_001.jpg (GRAPHIC) — 16KB
• ex5-1_002.jpg (GRAPHIC) — 16KB
• 0001493152-24-034991.txt ( ) — 14939KB
• cdt-20240630.xsd (EX-101.SCH) — 80KB
• cdt-20240630_cal.xml (EX-101.CAL) — 89KB
• cdt-20240630_def.xml (EX-101.DEF) — 356KB
• cdt-20240630_lab.xml (EX-101.LAB) — 571KB
• cdt-20240630_pre.xml (EX-101.PRE) — 480KB
• forms-1_htm.xml (XML) — 3003KB

USE OF PROCEEDS

USE OF PROCEEDS 40 MARKET PRICE OF OUR COMMON STOCK AND DIVIDEND INFORMATION 41

BUSINESS

BUSINESS 42 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 75 MANAGEMENT 87 EXECUTIVE AND DIRECTOR COMPENSATION 93 BENEFICIAL OWNERSHIP OF SECURITIES 98 SELLING SECURITYHOLDERS 100 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 102 DESCRIPTION OF OUR SECURITIES 105 PLAN OF DISTRIBUTION 108 LEGAL MATTERS 111 EXPERTS 111 WHERE YOU CAN FIND MORE INFORMATION 111 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus. No one has been authorized to provide you with information that is different from that contained in this prospectus. This prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this prospectus is accurate as of any date other than that date. i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the U.S. Securities Exchange Commission (the "SEC"), under which the Selling Securityholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholders of the securities offered by them described in this prospectus. Neither we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any applicable prospectus supplement, or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholders will make an offer to sell these securities in any jurisdiction where such offer or sale is not permitted. No dealer, salesperson, or other person is authorized to give an

Risk Factors

Risk Factors Our business is subject to numerous risks and uncertainties, including those highlighted in the section entitled "Risk Factors," which illuminate challenges that we face in connection with the successful implementation of our strategy and the growth of our business. The following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could cause a decline in the price of shares of our securities and result in a loss of all or a portion of your investment: There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not be available on acceptable terms, or at all. Our business is dependent on the successful development, regulatory approval, and commercialization of AZD1656, AZD5658, and AZD5904. Preclinical drug development for our clinical assets is expensive, time-consuming, and uncertain. It is difficult to accurately predict the time and cost of development and of subsequently obtaining regulatory approval for AZD1656. We may not be successful in our efforts to use and expand our research and development platform to build a pipeline of clinical assets. Our clinical trials may fail to adequately demonstrate the safety and efficacy of our clinical assets, which could prevent or delay regulatory approval and commercialization. We may be unable to obtain regulatory approval for our early-stage clinical assets under applicable regulatory requirements. We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate. 5 We currently rely on, and expect to continue to rely on, third-party CROs and other third parties to conduct and oversee our clinical trials and other aspects of product development. We currently rely on agreements with a related party and third parties for the pur

View Full Filing

View this S-1 filing on SEC EDGAR